Fusion Pharmaceuticals To Present At The 2021 Jefferies London Healthcare Conference
Fusion Pharmaceuticals (Nasdaq: FUSN) announces its presentation at the 2021 Jefferies London Healthcare Conference on November 18, 2021, at 8:00 am GMT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Fusion Pharmaceuticals (Nasdaq: FUSN) announces its presentation at the 2021 Jefferies London Healthcare Conference on November 18, 2021, at 8:00 am GMT. Chief Executive Officer John Valliant, Ph.D. will represent the company. A recording will be available for on-demand viewing post-event.
The company develops next-generation radiopharmaceuticals, including its lead program FPI-1434, currently in Phase 1 clinical trials. Fusion also collaborates with AstraZeneca and Merck to advance its innovative therapies.
Details
News Market Reaction – FUSN
The recorded move for FUSN in the trading session of this news was -2.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAMILTON, Ontario and BOSTON, Nov. 11, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2021 Jefferies London Healthcare Conference. A recording of the presentation will be made available for on-demand viewing on Thursday, November 18, 2021 at 8:00am GMT. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.
A webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear™ linker technology, Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), advancing to a Phase 1 study following the recent investigational new drug (IND) clearance; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion and Hamilton, Ontario-based McMaster University are building a current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company's growing pipeline of TATs.
View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-2021-jefferies-london-healthcare-conference-301422518.html
SOURCE Fusion Pharmaceuticals Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.